Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PRDM14-targeting nucleic acid medicine in breast cancer
jRCT2031190181Phase 1Active, not recruiting
- Sponsor
- NanoCarrier Co., Ltd.
- Start
- Sep 2020
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SRN-14 + GL2-800 in breast cancer, sponsored by NanoCarrier Co., Ltd. Primary endpoint: safety. Started Sep 2020; status: active, not recruiting.
02
Drugs
SRN-14 + GL2-800
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031190181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190181.